NCT01904279View on ClinicalTrials.gov

A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG

Tocilizumab

Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks

Trial Locations (35)

1270

Buenos Aires

2145

Westmead

3052

Parkville

13353

Berlin

16147

Genoa

27710

Durham

28034

Madrid

28046

Madrid

28203

Charlotte

50139

Florence

53757

Sankt Augustin

60611

Chicago

60637

Chicago

64460

Monterrey

74135

Tulsa

79106

Freiburg im Breisgau

84109

Salt Lake City

94275

Le Kremlin-Bicêtre

98105

Seattle

115522

Moscow

119991

Moscow

06106

Hartford

07601

Hackensack

45229-3039

Cincinnati

20551-030

Rio de Janeiro

21941-912

Rio de Janeiro

05403-000

São Paulo

22793-080

São Paulo

T3B 6A8

Calgary

K1H 8L1

Ottawa

M5G 1X8

Toronto

00165

Rome

08950

Esplugas de Llobregat

BS2 8BJ

Bristol

L12 2AP

Liverpool

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01904279 - A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA) | Biotech Hunter | Biotech Hunter